Clinical Roundup UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer January 30, 2026Vol.52 No.04
Clinical Roundup Most patients support use of AI to help read mammograms with doctor oversight, UTSW survey finds January 30, 2026Vol.52 No.04
Drugs & Targets FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM January 30, 2026Vol.52 No.04
Drugs & Targets Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC January 30, 2026Vol.52 No.04
Drugs & Targets Labcorp and Roche collaborate to expand access to advanced precision testing January 30, 2026Vol.52 No.04
Drugs & Targets HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline January 30, 2026Vol.52 No.04
Drugs & Targets ACR names University Hospital of Bern first international ARCH AI Site January 30, 2026Vol.52 No.04
Premarin’s 84-year hold on the market ends as FDA approves a generic versionTrade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer January 23, 2026Vol.52 No.03By Claire Marie Porter
Capitol Hill Spending bill passed by the House gives NIH $415M raise, NCI gets $128MLegislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched January 23, 2026Vol.52 No.03By Jacquelyn Cobb
Capitol Hill Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill January 23, 2026Vol.52 No.03By Jacquelyn Cobb
